Top Tweets for #ILC7

over 1 year ago

Can we predict response to bsAbs? •“Hot” immune environments (inflammatory) respond better to bispecific antibodies. •CAR-T therapy works independently of immune microenvironment. Ref: Tumurulu et al, Blood 2025. #bsAbs #CAR_T #DLBCL #ILC7 By Dr. Albabtain 💎💎💎💎💎

abouabdrahman0's tweet photo. Can we predict response to bsAbs?
•“Hot” immune environments (inflammatory) respond better to bispecific antibodies.
•CAR-T therapy works independently of immune microenvironment.

Ref: Tumurulu et al, Blood 2025.

#bsAbs #CAR_T #DLBCL #ILC7

By Dr. Albabtain 💎💎💎💎💎 https://t.co/T3bjj3iTZR

246

Ahmed Kotb @AhmedKo45911157

over 1 year ago

New Drugs in First Salvage for cHL BV combos (BV+chemo, Benda-BV, BV-ICE) → CR 61–79% Checkpoint combos (Nivo-BV, Pembro-GVD) → CR 67–92% High PFS: up to 91% at 3–5 years Better responses = improved ASCT outcomes! #HodgkinLymphoma #BV #Nivolumab #Pembrolizumab #ILC7

AhmedKo45911157's tweet photo. New Drugs in First Salvage for cHL

BV combos (BV+chemo, Benda-BV, BV-ICE) → CR 61–79%
Checkpoint combos (Nivo-BV, Pembro-GVD) → CR 67–92%
High PFS: up to 91% at 3–5 years
Better responses = improved ASCT outcomes!
#HodgkinLymphoma #BV #Nivolumab #Pembrolizumab #ILC7 https://t.co/T1E0Jmi8c8

513

Ahmed Kotb @AhmedKo45911157

over 1 year ago

Practical Approach to R/R cHL Primary refractory: CPI- or BV-based salvage Relapse: After CPI → BV salvage After BV → CPI salvage Transplant ineligible: CPI mono, BV+Nivo, RT, or chemo Post-ASCT: BV maintenance if BV-naïve #HodgkinLymphoma #RelapsedHL #Checkpoint #ILC7

$AhmedKo45911157's tweet photo. Practical Approach to R/R cHL Primary refractory: CPI- or BV-based salvage Relapse: After CPI → BV salvage After BV → CPI salvage Transplant ineligible: CPI mono, BV+Nivo, RT, or chemo Post-ASCT: BV maintenance if BV-naïve #HodgkinLymphoma #RelapsedHL #Checkpoint #ILC7 https://t.co/NurGkpO6so$

494

Ahmed Kotb @AhmedKo45911157

over 1 year ago

PD-1 Blockade = New Standard in Advanced cHL Nivo-AVD preferred: better PFS & safer than BV-AVD Safe in elderly BrECADD: potent but more toxic, best for young Use BV-based in autoimmune pts #HodgkinLymphoma #NivoAVD #PD1Blockade #ILC7 #Immunotherapy

AhmedKo45911157's tweet photo. PD-1 Blockade = New Standard in Advanced cHL

Nivo-AVD preferred: better PFS & safer than BV-AVD

Safe in elderly

BrECADD: potent but more toxic, best for young

Use BV-based in autoimmune pts

#HodgkinLymphoma #NivoAVD #PD1Blockade #ILC7 #Immunotherapy https://t.co/wb9EnjLX9t

763

Ahmed Kotb @AhmedKo45911157

over 1 year ago

HD21: BrECADD vs escBEACOPP in Advanced HL Patients ≤60 yrs with stage IIB–IV PFS: BrECADD 94% vs eBEACOPP 91% HR: 0.66 (p = 0.035) Lower toxicity with BrECADD Brentuximab adds efficacy with better tolerability! #HodgkinLymphoma #BrECADD #BEACOPP #ILC7 #HL

AhmedKo45911157's tweet photo. HD21: BrECADD vs escBEACOPP in Advanced HL
Patients ≤60 yrs with stage IIB–IV

PFS:
BrECADD 94% vs eBEACOPP 91%

HR: 0.66 (p = 0.035)

Lower toxicity with BrECADD

Brentuximab adds efficacy with better tolerability!
#HodgkinLymphoma #BrECADD #BEACOPP #ILC7 #HL https://t.co/J8zKkwhDOg

542

Ahmed Kotb @AhmedKo45911157

over 1 year ago

SWOG S1826: Nivolumab-AVD vs BV-AVD in Advanced HL PFS: 92% (N-AVD) vs 83% (BV-AVD) HR: 0.45 — favoring Nivolumab Benefit consistent across age, IPS, stage, bulk G-CSF required in both arms N-AVD is emerging as a superior frontline option #HodgkinLymphoma #Nivolumab #BVAVD #ILC7

AhmedKo45911157's tweet photo. SWOG S1826: Nivolumab-AVD vs BV-AVD in Advanced HL

PFS: 92% (N-AVD) vs 83% (BV-AVD)
HR: 0.45 — favoring Nivolumab
Benefit consistent across age, IPS, stage, bulk
G-CSF required in both arms
N-AVD is emerging as a superior frontline option
#HodgkinLymphoma #Nivolumab #BVAVD #ILC7 https://t.co/ZJfMOkj419

428

Ahmed Kotb @AhmedKo45911157

over 1 year ago

ECHELON-1: BV-AVD vs ABVD in Advanced HL 6-yr PFS: 82.3% (BV-AVD) vs 74.5% 6-yr OS: 93.9% vs 89.4% AE trade-off: More neutropenia, neuropathy (BV-AVD) 19% had persistent neuropathy GCSF mandatory with BV-AVD #HodgkinLymphoma #BVAVD #ECHELON1 #ILC7

AhmedKo45911157's tweet photo. ECHELON-1: BV-AVD vs ABVD in Advanced HL

6-yr PFS: 82.3% (BV-AVD) vs 74.5%

6-yr OS: 93.9% vs 89.4%

AE trade-off:

More neutropenia, neuropathy (BV-AVD)

19% had persistent neuropathy

GCSF mandatory with BV-AVD

#HodgkinLymphoma #BVAVD #ECHELON1 #ILC7 https://t.co/oftETte2Jo

Ahmed Kotb @AhmedKo45911157

over 1 year ago

Advanced-Stage HL: PET2-Guided Approach After 2 ABVD: PET– (84%) → Randomized to 4 ABVD vs 4 AVD (similar PFS, fewer AEs with AVD) PET+ (16%) → Escalated to BEACOPP (improved outcomes) Toxicity: AVD safer than ABVD (↓ fever, infection, pulmonary) #HodgkinLymphoma #ILC7

AhmedKo45911157's tweet photo. Advanced-Stage HL: PET2-Guided Approach

After 2 ABVD:

PET– (84%) → Randomized to 4 ABVD vs 4 AVD (similar PFS, fewer AEs with AVD)

PET+ (16%) → Escalated to BEACOPP (improved outcomes)

Toxicity:
AVD safer than ABVD (↓ fever, infection, pulmonary)

#HodgkinLymphoma #ILC7 https://t.co/MUfKKuQ69p

Ahmed Kotb @AhmedKo45911157

over 1 year ago

Risk Stratification in Early-Stage Hodgkin Lymphoma (ESHL) Different guidelines, same patient — different risk labels: GHSG: Age, B-symptoms, MMR >0.33, >2 nodal sites EORTC: MTR >0.35, >3 nodal sites NCCN: Any B-symptoms, bulky >10 cm #ILC7

AhmedKo45911157's tweet photo. Risk Stratification in Early-Stage Hodgkin Lymphoma (ESHL)

Different guidelines, same patient — different risk labels:

GHSG: Age, B-symptoms, MMR >0.33, >2 nodal sites

EORTC: MTR >0.35, >3 nodal sites

NCCN: Any B-symptoms, bulky >10 cm

#ILC7 https://t.co/wVfwIdzrLj

656

Ahmed Kotb @AhmedKo45911157

over 1 year ago

📊 FL: Bispecifics vs CAR-T Bispecifics ✔ Outpatient, well-tolerated ✔ Broader use incl. poor PS ➖ Lower RR, outcomes pending CAR-T ✔ Higher RR, long-term remission ➖ More toxic, for fit patients only #FL #CART #Bispecifics #ILC7

AhmedKo45911157's tweet photo. 📊 FL: Bispecifics vs CAR-T

Bispecifics
✔ Outpatient, well-tolerated
✔ Broader use incl. poor PS
➖ Lower RR, outcomes pending

CAR-T
✔ Higher RR, long-term remission
➖ More toxic, for fit patients only

#FL #CART #Bispecifics #ILC7 https://t.co/QZ6TxWmf2s

834

Ahmed Kotb @AhmedKo45911157

over 1 year ago

📋 FL Relapse Management 🟥 Aggressive: High LDH, TTP <6 mo → Salvage chemo → Auto/Allo-SCT, CAR-T, Bispecifics 🟩 Indolent: Low bulk → R², CAR-T/Bispecific (if ≥2 prior lines), Tazemetostat, chemo #FL #Relapse #CART #Lymphoma #ILC7

AhmedKo45911157's tweet photo. 📋 FL Relapse Management

🟥 Aggressive: High LDH, TTP <6 mo → Salvage chemo → Auto/Allo-SCT, CAR-T, Bispecifics
🟩 Indolent: Low bulk → R², CAR-T/Bispecific (if ≥2 prior lines), Tazemetostat, chemo

#FL #Relapse #CART #Lymphoma #ILC7 https://t.co/QErHoS9UIJ

Ahmed Kotb @AhmedKo45911157

over 1 year ago

📌 MCL: Evolving Landscape by Davies • Rapid progress in MCL treatment • Better ID of high-risk patients • Novel agents added earlier (Triangle/ECHO) • Shift toward chemo-free regimens • T-cell therapies gaining earlier use • Many combos under study #MCL #Lymphoma #ILC7

AhmedKo45911157's tweet photo. 📌 MCL: Evolving Landscape by Davies
• Rapid progress in MCL treatment
• Better ID of high-risk patients
• Novel agents added earlier (Triangle/ECHO)
• Shift toward chemo-free regimens
• T-cell therapies gaining earlier use
• Many combos under study
#MCL #Lymphoma #ILC7 https://t.co/7dIvzkkkJR

259

Ahmed Kotb @AhmedKo45911157

over 1 year ago

🧬 Allo-SCT in Mantle Cell Lymphoma • Consider in primary chemorefractory or very high-risk cases • 2-yr OS: 80% (TP53 WT) vs 70% (TP53 altered) • May overcome TP53 poor prognosis ⚠️ High NRM, select fit patients #MCL #AlloSCT #TP53 #Hematology #ILC7

$AhmedKo45911157's tweet photo. 🧬 Allo-SCT in Mantle Cell Lymphoma • Consider in primary chemorefractory or very high-risk cases • 2-yr OS: 80% (TP53 WT) vs 70% (TP53 altered) • May overcome TP53 poor prognosis ⚠️ High NRM, select fit patients #MCL #AlloSCT #TP53 #Hematology #ILC7 https://t.co/nM1FKCzDL8$

319

Ahmed Kotb @AhmedKo45911157

over 1 year ago

📊 Risk Stratification in Mantle Cell Lymphoma (MCL) 🔹 Low Risk: • Ki-67 ≤10% • SOX11– • IGHV hypermutated • Stable karyotype 🔺 High Risk: • Blastoid/pleomorphic variant • Ki-67 >30% • TP53 mutation • Complex karyotype #MCL #Lymphoma #Risk #Hematology #ILC7

AhmedKo45911157's tweet photo. 📊 Risk Stratification in Mantle Cell Lymphoma (MCL)
🔹 Low Risk:
• Ki-67 ≤10%
• SOX11–
• IGHV hypermutated
• Stable karyotype

🔺 High Risk:
• Blastoid/pleomorphic variant
• Ki-67 >30%
• TP53 mutation
• Complex karyotype

#MCL #Lymphoma #Risk #Hematology #ILC7 https://t.co/fRbmAxFIPO

Ahmed Kotb @AhmedKo45911157

over 1 year ago

📌 Mantle Cell Lymphoma (MCL) • Mature B-cell NHL, 5–7% of adult NHLs • ♂ Predominance (3:1), median age ~68 yrs • CD5+, small–medium cells • Morphology: Blastoid, pleomorphic, small-cell, MZ-like • >95% with t(11;14) → CCND1 overexpression #MCL #Lymphoma #Hemato #ILC7

AhmedKo45911157's tweet photo. 📌 Mantle Cell Lymphoma (MCL)
• Mature B-cell NHL, 5–7% of adult NHLs
• ♂ Predominance (3:1), median age ~68 yrs
• CD5+, small–medium cells
• Morphology: Blastoid, pleomorphic, small-cell, MZ-like
• >95% with t(11;14) → CCND1 overexpression
#MCL #Lymphoma #Hemato #ILC7 https://t.co/7tUlOHxlOs

701

Ahmed Kotb @AhmedKo45911157

over 1 year ago

🧬 Plasmablastic Lymphoma (PBL) Pathogenesis • EBV infects naïve B cells and blocks apoptosis • Inflammation promotes malignant transformation • MYC mutation drives B cell dysregulation • Key pathways: JAK/STAT, PI3K-AKT, MAPK, NOTCH #PBL #Lymphoma #EBV #Hematology #ILC7

AhmedKo45911157's tweet photo. 🧬 Plasmablastic Lymphoma (PBL) Pathogenesis
• EBV infects naïve B cells and blocks apoptosis
• Inflammation promotes malignant transformation
• MYC mutation drives B cell dysregulation
• Key pathways: JAK/STAT, PI3K-AKT, MAPK, NOTCH

#PBL #Lymphoma #EBV #Hematology #ILC7 https://t.co/vZSVYfqNLl

710

Ahmed Kotb @AhmedKo45911157

over 1 year ago

Current r/r DLBCL management 🔁 🔹 ~50% ASCT-eligible ➡️ Salvage chemo ➡️ ASCT 🔹 Only ~25–35% cured 🔹 Others need 2L/3L options: CAR-T Polatuzumab + BR Tafasitamab-lenalidomide Allo-SCT, Selinexor, trials 🔚 Multiline strategy needed! #Lymphoma #DLBCL #HemeOnc #CAR_T #ILC7

AhmedKo45911157's tweet photo. Current r/r DLBCL management 🔁
🔹 ~50% ASCT-eligible ➡️ Salvage chemo ➡️ ASCT
🔹 Only ~25–35% cured
🔹 Others need 2L/3L options:

CAR-T

Polatuzumab + BR

Tafasitamab-lenalidomide

Allo-SCT, Selinexor, trials
🔚 Multiline strategy needed!
#Lymphoma #DLBCL #HemeOnc #CAR_T #ILC7 https://t.co/Tbs13I8teh

Ahmed Kotb @AhmedKo45911157

over 1 year ago

#ZUMA23 explores Axi-cel as 1st-line vs chemo in high-risk LBCL N=300 Eligibility: DLBCL, HGBL, tFL/MZL, IPI ≥4 Arm 1: Axi-cel CAR T Arm 2: R-CHOP / DA-EPOCH-R Endpoints: ✔ EFS ✔ PFS ✔ OS ✔ CR Rate ✔ QoL Trial ID: NCT05605899 #CAR_T #Lymphoma #ILC7

AhmedKo45911157's tweet photo. #ZUMA23 explores Axi-cel as 1st-line vs chemo in high-risk LBCL
N=300
Eligibility: DLBCL, HGBL, tFL/MZL, IPI ≥4
Arm 1: Axi-cel CAR T
Arm 2: R-CHOP / DA-EPOCH-R
Endpoints:
✔ EFS
✔ PFS
✔ OS
✔ CR Rate
✔ QoL
Trial ID: NCT05605899
#CAR_T #Lymphoma #ILC7 https://t.co/lUIBTendoJ

389

Ahmed Kotb @AhmedKo45911157

over 1 year ago

Rituximab response matters! In PTLD, early response to rituximab guides therapy: ✅ CR → continue rituximab ❌ No CR → switch to R-CHOP Tailored approach = better outcomes! #ILC7 #PTLD #Lymphoma #Transplant #Rituximab #Oncology @zinzani

AhmedKo45911157's tweet photo. Rituximab response matters!
In PTLD, early response to rituximab guides therapy:
✅ CR → continue rituximab
❌ No CR → switch to R-CHOP
Tailored approach = better outcomes!
#ILC7 #PTLD #Lymphoma #Transplant #Rituximab #Oncology
@zinzani https://t.co/cYUYbQYW3Z

330

Ahmed Kotb @AhmedKo45911157

over 1 year ago

rly vs Late PTLD in adults: 🧬 Early: EBV+ tumors, graft involvement, better 1y survival (65%) 🦠 Late: EBV– tumors, more extranodal, high C-MYC, worse survival (53%) 💊 Both need immunosuppression control 🔬Bortezomib may help late PTLD post-HSCT #ILC7 #PTLD #TransplantLymphoma

AhmedKo45911157's tweet photo. rly vs Late PTLD in adults:

🧬 Early: EBV+ tumors, graft involvement, better 1y survival (65%)
🦠 Late: EBV– tumors, more extranodal, high C-MYC, worse survival (53%)
💊 Both need immunosuppression control
🔬Bortezomib may help late PTLD post-HSCT
#ILC7 #PTLD #TransplantLymphoma https://t.co/IR1k7Pz1zI

940

Top Tweets for #ILC7

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users